Background: Chemical pleurodesis is used for the management of malignant /recurrent pleural effusion and pneumothorax.Malignant pleural effusion is diagnosed on histopathology or malignant cells in pleural fluid. Pneumothorax is diagnosed by chestradiograph. Pleurodesis can be performed surgically or by using medical agents. Various pleurodesis agents have been used e.g.Tetracycline.Bleomycin. Talc and lodopovidone with different success and complications rates.Objective: This study was conducted to know the efficacy and safety of lodopovidone as pleurodesis agent in themanagement of pleural effusion (malignant/recurrent) and recurrent pneumothorax.Material and Methods: This was a descriptive study conducted at department of Pulmonology Lady Reading HospitalPeshawar from February 2018 to May 2019.Results:A Total of 213 patients were included in the study, among which 120 (56.3%) were males and 93 (43.6%) werefemales. Age range was from 20 to 83 years. One hundred and thirty eight patients (74.8%) had malignant pleural effusion and75 (35.2%) had recurrent pneumothorax. The success rate with lodopovidone pleurodesis was 85 % (181) as a whole with afailure rate of 13 %( 28) in pleural effusion and 2 %( 4) in pneumothorax. Chest pain (65.7%) was the most common side effectfollowed by fever (24.4%) and dyspnea (12.2%).No serious side effects were observed in this study.Conclusion: lodopovidone is easily available, safer, cheaper and effective agent for chemical pleurodesis in pneumothorax,malignant/recurrent pleural effusion.Keywords: Pleurodesis, lodopovidone. Malignant, Pleural Effusion, Pneumothorax.
RECURRENT PLEURAL EFFUSION IN PRIMARY SYSTEMIC AMYLOIDOSIS – A RARE MANIFESTATION OF A RARE DISEASE
